Form 4: Humacyte CFO Dale A. Sander Reports Stock Option Grant
SEC Filing
Humacyte's CFO, Dale A. Sander, reports the acquisition of stock options exercisable for 283,101 shares of common stock.
Summary
- Dale A. Sander, CFO and Chief Corporate Development Officer of Humacyte, Inc., filed a Form 4 on January 23, 2025, reporting a transaction.
- On January 21, 2025, Sander acquired stock options for 283,101 shares of Humacyte's common stock at an exercise price of $4.56.
- The options vest over time, with the first 25% becoming exercisable on January 21, 2026, and the remainder vesting monthly until January 21, 2029.
- Following the reported transaction, Sander directly owns options exercisable for 283,101 shares.
Sentiment
Score: 5
Explanation: Neutral sentiment as it is a standard regulatory filing related to executive compensation.
Positives
- The grant of stock options to the CFO aligns his interests with those of the shareholders.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The stock option grant aligns management's interests with shareholders, potentially incentivizing value creation.
Key Dates
| Date | Description |
|---|---|
| 01/21/2025 | Date of stock option grant |
| 01/21/2026 | First 25% of options become exercisable |
| 01/21/2029 | Options fully vested |
| 01/23/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.